• AIM ImmunoTech entered a registered direct offering with a concurrent private placement for gross proceeds of about $2.65 million.
• Registered direct leg: 2,554,119 common shares priced at $0.52 per share; closing expected on or about June 10, 2026.
• Private placement: 2,554,119 unregistered common shares or pre-funded warrants priced at $0.52 per share.
• Also issuing Class J warrants for up to 10,216,476 shares; $0.52 exercise price; 5-year term; exercisable subject to stockholder approval.
• Proceeds earmarked for clinical drug supply manufacturing, ongoing trials, planned Phase 3 activities, working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-028283), on June 11, 2026, and is solely responsible for the information contained therein.